DYP688 is an investigational medication being studied for its potential to treat metastatic uveal melanoma and other melanomas with specific genetic mutations. The trial aims to understand how safe and tolerable this medication is for patients and to determine the best dose for future studies. Additionally, the trial seeks to evaluate how effective DYP688 is in reducing tumor size or slowing the progression of the disease.

Metastatic Uveal Melanoma – This is a type of cancer that originates in the eye’s uveal tract and spreads to other parts of the body. It typically begins in the pigmented cells of the eye and can progress to affect organs such as the liver. The disease is characterized by the uncontrolled growth of melanocytes, which are the cells responsible for producing pigment. As it advances, it can lead to symptoms such as vision changes or loss, and eventually, systemic symptoms as it metastasizes. The progression of the disease can vary, but it often involves the spread to distant organs, complicating treatment and management.

Other GNAQ/11 Mutant Melanomas – These are melanomas that occur due to mutations in the GNAQ or GNA11 genes, which are involved in cell signaling pathways. These mutations can lead to abnormal cell growth and the development of melanoma in areas such as the skin or mucosal surfaces. The disease progresses as the mutated cells continue to divide uncontrollably, potentially leading to the formation of tumors. Over time, these melanomas can invade surrounding tissues and may spread to other parts of the body. The progression and behavior of these melanomas can vary depending on the location and extent of the mutation.